Source comparison
MK-677 Ipamorelin Protocol Cycle Research: Outcomes Comparison
MK-677 monotherapy (evening dose) 25mg QD None +45–60% from baseline Simple dosing, sustained GH elevation, minimal injection burden Effective for baseline IGF-1 boost but lacks pulsatile peaks. Suboptimal for anabolic signalling research Ipamorelin monotherap
This comparison does not assign a generated winner or score.
- MK-677 monotherapy (evening dose)
- 25mg QD
- None
- +45–60% from baseline
- Simple dosing, sustained GH elevation, minimal injection burden
- Effective for baseline IGF-1 boost but lacks pulsatile peaks. Suboptimal for anabolic signalling research
- Ipamorelin monotherapy (3x daily)
- 300mcg TID
- +30–50% from baseline
- Preserves natural GH pulsatility, no appetite increase
- Requires multiple daily injections; lacks the sustained elevation MK-677 provides. Less total GH exposure
- Synergistic stack (evening MK-677 + timed ipamorelin)
- 20mg QD
- 250mcg BID–TID
- +70–95% from baseline
- Multiplicative GH amplitude, sustained + pulsatile dynamics
- Gold standard for mk-677 ipamorelin protocol cycle research. Highest IGF-1 output, best receptor dynamics
- High-dose MK-677 only
- 50mg QD
- +50–65% from baseline
- Maximum single-compound stimulation
- Receptor saturation occurs at 25mg. Doses above this increase side effects (water retention, lethargy) without proportional GH gain